These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 12887493)

  • 21. Combined detrusor-trigone BTX-A injections for urinary incontinence secondary to neurogenic detrusor overactivity.
    Hui C; Keji X; Chonghe J; Ping T; Rubiao O; Jianweng Z; Xiangrong D; Liling Z; Maping H; Qingqing L; Qiuling L; Jiebing H; Tanghai H
    Spinal Cord; 2016 Jan; 54(1):46-50. PubMed ID: 26261074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Botulinum toxin A in the treatment of spinal cord injury patients with refractory neurogenic detrusor overactivity.
    Alvares RA; Silva JA; Barboza AL; Monteiro RT
    Int Braz J Urol; 2010; 36(6):732-7. PubMed ID: 21176280
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction.
    Ghalayini IF; Al-Ghazo MA
    Neurourol Urodyn; 2007; 26(4):531-536. PubMed ID: 17330289
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [INJECTION OF BOTULINUM TOXIN TYPE A IN THE BLADDER DETRUSOR AND SUBMUCOSA IN PATIENTS WITH OVERACTIVE BLADDER WITHOUT DETRUSOR OVERACTIVITY].
    Krivoborodov GG; Tur EI; Efremov NS
    Urologiia; 2015; (2):31-4. PubMed ID: 26237802
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Re: botulinum toxin A modulates afferent fibers in neurogenic detrusor overactivity.
    Wein AJ
    J Urol; 2014 May; 191(5):1340-1. PubMed ID: 24745503
    [No Abstract]   [Full Text] [Related]  

  • 26. Botulinum toxin for the management of bladder dysfunction.
    Schurch B
    Drugs; 2006; 66(10):1301-18. PubMed ID: 16903766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Botulinum toxin type A for the treatment of lower urinary tract disorders.
    Yokoyama T; Chancellor MB; Oguma K; Yamamoto Y; Suzuki T; Kumon H; Nagai A
    Int J Urol; 2012 Mar; 19(3):202-15. PubMed ID: 22220916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of botulinum a toxin in the treatment of voiding dysfunction due to detrusor underactivity.
    Kuo HC
    Urology; 2003 Mar; 61(3):550-4. PubMed ID: 12639645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results.
    Schurch B; Stöhrer M; Kramer G; Schmid DM; Gaul G; Hauri D
    J Urol; 2000 Sep; 164(3 Pt 1):692-7. PubMed ID: 10953127
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Changes in Management of Poorly Compliant Bladder in Botulinum Toxin A Era.
    Prakash NS; Lopategui DM; Gomez C
    Curr Urol Rep; 2017 Aug; 18(8):64. PubMed ID: 28689244
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Botulinum toxin A for the Treatment of Overactive Bladder.
    Hsieh PF; Chiu HC; Chen KC; Chang CH; Chou EC
    Toxins (Basel); 2016 Feb; 8(3):. PubMed ID: 26938559
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence.
    Grosse J; Kramer G; Stöhrer M
    Eur Urol; 2005 May; 47(5):653-9. PubMed ID: 15826758
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Criteria and best clinical practice guidelines for first intradetrusor injection of botulinum toxin type A to treat neurogenic detrusor overactivity].
    Perrouin-Verbe B; Ruffion A; Gamé X; Denys P; Kerdraon J; Karsenty G; de Sèze M; Haab F; Saussine C; Soler JM; Amarenco G; Chartier-Kastler E
    Prog Urol; 2009 Jun; 19(6):372-82. PubMed ID: 19467455
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tips and Tricks in Intra-Detrusor Botulinum Toxin A (BoNTA) Injections.
    Corcos J; Biardeau X; Aharony S
    World J Urol; 2015 Jun; 33(6):899-901. PubMed ID: 26217823
    [No Abstract]   [Full Text] [Related]  

  • 35. Botulinum toxin injection for lower urinary tract dysfunction.
    Kuo YC; Kuo HC
    Int J Urol; 2013 Jan; 20(1):40-55. PubMed ID: 22571329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Botulinum toxin type A in patients with Parkinson's disease and refractory overactive bladder.
    Giannantoni A; Conte A; Proietti S; Giovannozzi S; Rossi A; Fabbrini G; Porena M; Berardelli A
    J Urol; 2011 Sep; 186(3):960-4. PubMed ID: 21791351
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discontinuation rates and inter-injection interval for repeated intravesical botulinum toxin type A injections for detrusor overactivity.
    Veeratterapillay R; Harding C; Teo L; Vasdev N; Abroaf A; Dorkin TJ; Pickard RS; Hasan T; Thorpe AC
    Int J Urol; 2014 Feb; 21(2):175-8. PubMed ID: 23819724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Input from a specialized nurse consultation in the management of detrusor overactivity treated with intradetrusor injections of botulinum toxin in urology department. Pilot study].
    Le Gal S; Safsaf A; Galliot I; Catovic B; Grise P
    Prog Urol; 2010 Sep; 20(8):584-9. PubMed ID: 20832036
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Botulinum toxin for the lower urinary tract.
    Chuang YC; Kuo HC; Chancellor MB
    BJU Int; 2010 Apr; 105(8):1046-58. PubMed ID: 22299133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Value of Urinary Brain-Derived Neurotrophic Factor Levels on the Assessment of Botulinum Toxin Type A Treatment for Neurogenic Detrusor Overactivity in Children with Myelodysplasia.
    Sekerci CA; Tanidir Y; Toprak T; Basok BI; Isman F; Simsek F; Akbal C; Tarcan T
    J Urol; 2019 Jan; 201(1):174-180. PubMed ID: 30577408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.